Trial · NCT01620138
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
NCT01620138, Phase 2, Phase 3, Completed, Universidade Federal do Rio de Janeiro; results first posted 2016-06-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas. Trials, record NCT01620138. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01620138
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
- NCT number
- NCT01620138
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 21 participants, actual
- Lead sponsor
- Universidade Federal do Rio de Janeiro
- Conditions
- Non-functioning Pituitary Adenomas, Prolactinomas
- Interventions
- Pasireotide, cabergoline
- First posted
- 2012-06-15
- Last updated
- 2016-08-22
- Results first posted
- 2016-06-16
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma | Baseline to six months | Magnetic resonance imaging (MRI) of the sella and prolactin will be performed before (baseline) and after 6 months of treatment with cabergoline or pasireotide. Disease progression will be defined as tumor growth \> 25%, stable disease as changes \< 25% and significant tumor shrinkage as \> 25% in tumor volume compared to baseline MRI (baseline to six months). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma | Baseline to six months | cmˆ3 | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma | Pasireotide | 3.8 | Full Range 3.46 to 4.58 | cmˆ3 | |
| Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma | Cabergoline | 29.35 | Full Range 2.55 to 51.93 | cmˆ3 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pasireotide | 12 | |
| Overall Study | STARTED | Cabergoline | 9 | |
| Overall Study | COMPLETED | Pasireotide | 6 | |
| Overall Study | COMPLETED | Cabergoline | 9 | |
| Overall Study | NOT COMPLETED | Pasireotide | 6 | |
| Overall Study | NOT COMPLETED | Cabergoline | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Endocrine disorders | Pasireotide | 1 | 12 | 1 |
| other | Hyperglycemia | Endocrine disorders | Cabergoline | 0 | 9 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Pasireotide | 1 | 12 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Cabergoline | 0 | 9 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pasireotide | ||
| Total, all-cause mortality | Cabergoline | ||
| Total, other adverse events | Pasireotide | 2 | 12 |
| Total, other adverse events | Cabergoline | 0 | 9 |
| Total, serious adverse events | Pasireotide | 0 | 12 |
| Total, serious adverse events | Cabergoline | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Pasireotide vs Cabergoline: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01620138
GET https://conductscience.org/api/trials/v1/NCT01620138/registered